CORAL – the proteome in neurological disease
The CORAL consortium (Community using Olink for Research on Alzheimer’s Disease and other neurological diseases) is a collaborative framework. Our objective is to accelerate the identification of proteins and mechanisms for neurological diseases, as well as the translation of novel biomarkers for neurological diseases to the clinic.
- Sharing experiences with biomarker development workflows, starting from cerebrospinal fluid (CSF) and plasma proteins on the Olink Proteomics platform
- Performing collaborative meta-analyses and other studies to identify novel mechanisms and biomarkers for neurological diseases.
The consortium project is taking shape, with the first kick-off meeting in July 2021. CORAL welcomes new members! For more information please contact Lisa Vermunt (CORAL project coordinator) and Charlotte Teunissen (CORAL project chair).
Introduction from Charlotte Teunissen
In the short video below, Professor Charlotte Teunissen explains the concept behind the CORAL collaborative initiative and how this consortium could benefit research into neurological diseases.
Each CORAL member will be working on human study collections from the general population, clinical trials or patients and is focused on neurological diseases such as Alzheimer’s disease, Lewy bodies dementia, Parkinson’s disease, Frontotemporal Dementia (FTD), Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Amyotrophic lateral sclerosis (ALS) and epilepsy. Together members can validate their findings and identify leads for cross-disease markers and mechanisms.
The aim of the CORAL consortium is to identify novel biomarkers and biological mechanisms for neurological diseases that are developed into biomarkers for diagnostic, prognostic, disease monitoring and/or treatment response evaluation.
CORAL is starting now and new members are welcomed, particularly groups that have already published or are working on their Olink proteomics dataset and are seeking to share experiences and collaborate with others.
To be a member of the CORAL consortium you have to be the PI of a study collection with Olink proteomics CSF or plasma data in patients with neurological disease and/or a control population. We also expect members to sign up to a Consortium Agreement, which details member conduct and authorship policy. We will organize ancillary events at conferences to share work and discuss projects. We will also allow members to use CORAL as a platform to exhibit their work.
The leadership for subprojects within the CORAL consortium rotates and members are encouraged to be active and suggest new subprojects.
Publications in the neurology field citing Olink
Olink protein biomarker panels have so far been cited in around 50 peer-reviewed publications related to neurology and neurological diseases, covering a broad range of applications and neurological conditions – SEE THE LATEST LIST HERE